---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000117"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:34:25.480116+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY

## Summary
- Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.
- Full-year 2024 revenue ~$73.1M-$73.3M vs $65.6M in 2023, YoY growth 11-12%.
- Orders booked in Q4 exceeded shipments, building robust backlog for 2025.
- CEO Roger Susi cites increasing demand expected to continue through 2025.
- Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2025.

## SEC filing metadata
- accession: 0001558370-25-000117
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000155837025000117/0001558370-25-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000155837025000117/irmd-20250110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000117
- JSON: https://secwatch.observer/filing/0001558370-25-000117.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.